HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • LipoADC™ Platform – K1
    • TRAFsome™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • LipoADC™ Platform – K1
    • TRAFsome™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (12)
  • Publications (14)
  • References (21)
  • Uncategorized (6)

Recent Posts

Post placeholder image
September 18, 2024

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 16, 2024

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 4, 2024

HighField Biopharmaceuticals Company Profile – 2024

by PJWCreative
Post placeholder image
September 3, 2024

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

by PJWCreative
Post placeholder image
August 8, 2024

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

by PJWCreative
Post placeholder image
June 24, 2024

HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
June 24, 2020 in References

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

PJWCreative 0 Like Post 0 Comment
Read More

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

© 2024 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc